Hi meg,
Your question relates to pursuing a secondary outcome, with using Cvac as an adjunct therapy to chemotherapy.
I believe they are doing this already with can-003 where patients in the osc group who progress are offered Cvac treatment also (someone correct me if I wrong)
This muddles OS a bit as you don't get a true indication of OS related to the drug alone. But I guess it let's you compare the benefit of administering te drug during remission rather than after progression.
With regards to canvas, it is really up to them. The biggest issue is cost. They aren't fully funded, so guaranteeing that many people to receive full courses is a lot of money. I don't think that will be possible. It's probably one to ask the team
- Forums
- ASX - By Stock
- IMM
- interim data from can-003 clinical trial
interim data from can-003 clinical trial, page-22
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M |
Open | High | Low | Value | Volume |
29.0¢ | 29.8¢ | 29.0¢ | $539.5K | 1.834M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 214062 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 469318 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 214062 | 0.290 |
19 | 266746 | 0.285 |
19 | 557602 | 0.280 |
6 | 224918 | 0.275 |
9 | 226781 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 469318 | 5 |
0.300 | 654947 | 7 |
0.305 | 155034 | 7 |
0.310 | 502791 | 5 |
0.315 | 142694 | 7 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |